|
|
 |
|
Viewing report
|
|
|
|
Neurodegenerative Disease: The Growing Market for Drugs used in the Treatment of Alzheimer's, Parkinson's and other Neurodegenerative Conditions
IMS Health, Oct 2005, Pages: 350
Neurodegenerative diseases are destined to become the next great health crusade over the next several decades. This will support sustaintable long-term sales growth of NDD products: the collective total sales of the eight markets reviewed in this report are set to more than double in size to over $10bn by 2013.
The market for products for Alzheimer's disease and Parkinson's disease is set to more than double in size over the coming decade. The growth of these therapy areas will be affected by a range of factors:
- The aging of the global population and more accurate diagnosis will foster market increases
- In a class yet to be affected by generic competition, growth in the Alzheimer's market will be driven by the launch of new types of drugs including GABA receptor modulators, anti-amyloid protein agents and nicotinic and cholinergic receptor agonists
- Vaccines and neuroprotective therapies will also play a role in the development of the Alzheimer's market
- Growth in the Parkinson's market will in the medium to long term be driven by the launch of glutamate receptor modulators, dopamine receptor agonists and reuptake inhibitors, and andrenergic and adenosine antagonists
- However, this market will be impacted heavily in the shorter term by loss of patent protection for leading dopamine agonists
- Payers' resistance to increasing healthcare costs will stimulate the growth of generics, as well as budget caps, price limits and non-approvals of expensive treatments across the neurodegenerative disease market
- Nevertheless, new products will enter this market at a premium relative to their effectiveness when compared with established treatments
Comprehensive coverage including:
- Detailed profiles of 10 leading manufacturers and the position of neurodegenerative disease products in their portfolios
- Detailed analysis of both the Alzheimer's disease and Parkinson's disease markets, including discussion of past, current and future performance
- Assessment of the role of AChE inhibitors in driving the recently-formed Alzheimer's disease market
- The impact of the arrival of the first of the next generation NMDA receptor antagonists on this market
- Assessment of the role of dopamine agonists as first-line therapy for Parkinson's disease
- The role played by COMT inhibitors as adjunctive therapies alongside levodopa in Parkinson's treatment
- The use of amantadine and anticholinergic drugs for symptomatic relief
- The impact of the arrival of the second-generation MAO-B inhibitor, rasagiline, on the Parkinson's market
- The impact of patent expiries
- Detailed profiles of 15 leading products – including clinical data, licensing, lifecycle management, competition, prospects
- Compounds in R&D - with drug profiles and analysis
Plus background information on neurodegenerative disease, with specific reference to Alzheimer's and Parkinson's disease:
- Epidemiology of neurodegenerative disease by region, selected countries, type, age, sex, ethnic group [see sample]
- Disease overview - definitions, classifications, risk factors, diagnosis and treatment, costs and consequences of neurodegenerative diseases
Key Findings
- Neurodegenerative disease (NDD) is a general term for a number of disorders that have different symptoms and effects, all of which act through the mechanism of compromising the brain's capacity to control itself or the body by damaging cells known as neurons that facilitate normal brain function
- Alzheimer's disease (AD) is the world's leading cause of dementia and the most prevalent NDD. 50-75% of dementia is estimated to be caused by this disease
- Parkinson's disease (PD) is the world's second commonest form of NDD. Parkinsonism is a term for a group of disorders that result in symptoms similar to those seen in classic PD NDDs are primarily diseases of older people. With the world's population living longer, the numbers of sufferers are set to rise over the next several decades
- NDDs constitute a disease category that the World Health Organization (WHO) calculates will become the world's second leading cause of death by the year 2040, overtaking cancer
- Onset of AD most commonly occurs after 65 years of age (only 2% of dementia occurs in patients under 65)
- Prevalence of AD is slightly higher in women than in men, but almost twice as many women live with dementia because of their longer life expectancy
- AD is usually divided into three distinct phases: mild, moderate and severe (also known as early-stage, mid-stage and late-stage) AD
- Onset of PD most commonly occurs after 60 years of age, but an early-onset form of the disease can strike those aged under 40
- Prevalence is slightly higher in men than in women
- Total NDD product sales more than doubled in dollar terms in the period 2000-2004 to reach almost $5.7bn
- The US is the world's single largest NDD products market, worth nearly $2.3bn in 2004. Japan and Germany were the next biggest markets
- In 2003, AD treatments overtook PD treatments to become the largest contributing element in the overall NDD products market
- Patients are most commonly treated for AD with a class of drugs known as AChE inhibitors, such as Eisai/Pfizer's Aricept (donepezil)
- Aricept is the global number-one AD drug, worth $1.8bn in 2004. The next largest brand was Novartis' Exelon (rivastigmine), another AChE inhibitor
Product samples
Samples for this product is available. Please Login/Register to download these samples.
Customers who bought this item also bought
Alzheimer’s and Parkinson’s Diseases - A Global Update of Market Trends & Opportunities
Commercial Insight: Parkinson's Disease - Japan and Europe to Drive Total Market Growth
Alzheimer Disease - New Drugs, Markets and Companies
The Global Market and Future Outlook for Neurodegenerative Disorder Therapies 2007
Alzheimer's Disease: Markets, Pipeline and Opportunities 2009
Global Alzheimer Drugs Market: An Analysis
Neurodegenerative Market Forecast to 2013
Forecast Insight: Parkinson's Disease - Market Upgrade following Evidence of Disease Slowing with Azilect
Mild Cognitive Impairment and Early Alzheimer's Disease: Detection and Diagnosis
Alzheimer's Disease Biomarkers, 2009
Mild Cognitive Impairment - Unlocking the Potential of Prodromal Alzheimer's Disease and Beyond
CNS Drug Discoveries: Parkinson's Disease Chapter
|
|
|
|
